Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.74 |
| ▸ | PPARG | P37231 | 1/20 | 0.74 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927869 | 0.89 | KDM4E (0.78) | MAPTRXFP1PPARGNCOA2KDM4E | |
| SCHEMBL10004185 | 0.85 | MAPT (0.58) | MAPTRXFP1PPARGNCOA2KDM4E | |
| SCHEMBL8197906 | 0.85 | ALDH1A1 (0.68) | MAPTRXFP1PPARGNCOA2KDM4E | |
| SCHEMBL4523689 | 0.84 | KMT2A (0.66) | MAPTRXFP1PPARGNCOA2KDM4E | |
| SCHEMBL4527926 | 0.84 | TSHR (0.61) | MAPTRXFP1PPARGNCOA2KDM4E | |
| SCHEMBL8202761 | 0.83 | KDM4E (0.65) | MAPTRXFP1PPARGNCOA2KDM4E | |
| SCHEMBL4523978 | 0.82 | KMT2A (0.62) | MAPTRXFP1PPARGNCOA2KDM4E | |
| SCHEMBL4505517 | 0.82 | KMT2A (0.62) | MAPTRXFP1PPARGNCOA2KDM4E | |
| SCHEMBL4514858 | 0.81 | KMT2A (0.67) | MAPTRXFP1PPARGNCOA2KDM4E | |
| SCHEMBL4524528 | 0.81 | KMT2A (0.61) | MAPTRXFP1PPARGNCOA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139499-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | CARDURION PHARMACEUTICALS LLC (US) | 2021-05-13 | — | — | US | disclosed |
| EP-3781155-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | Cardurion Pharmaceuticals, LLC (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10822346-B2 | Meglumine salts of thienopyrimidines | CARDURION PHARMACEUTICALS, LLC (US) | 2020-11-03 | — | — | US | disclosed |
| WO-2019204298-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | CARDURION PHARMACEUTICALS, LLC (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190315765-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | CARDURION PHARMACEUTICALS LLC (US) | 2019-10-17 | — | — | US | disclosed |
| EP-1908765-B1 | THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-8377944-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | GOTANDA KOTARO (JP) | 2013-01-24 | — | — | US | disclosed |
| US-8293754-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822346-B2 | Meglumine salts of thienopyrimidines | DPYD, TPMT, TYMP | MAPT 3198/4885RXFP1 3708/4885PPARG 919/4885 |
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | PDE9A, BPHL, THOP1 | MAPT 1619/4885RXFP1 739/4885PPARG 2660/4885 |
| US-20190315765-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | DPYD, TPMT, TYMP | MAPT 3198/4885RXFP1 3708/4885PPARG 919/4885 |
| US-20090203703-A1 | Thienopyrimidine Derivatives | PDE9A, BPHL, THOP1 | MAPT 1619/4885RXFP1 739/4885PPARG 2660/4885 |
| US-20210139499-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | DPYD, TPMT, TYMP | MAPT 3198/4885RXFP1 3708/4885PPARG 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.